Cargando…
Twenty Years of Anti-Vascular Endothelial Growth Factor Therapeutics in Neovascular Age-Related Macular Degeneration Treatment
Neovascular age-related macular degeneration (nAMD) is the primary disastrous retinal disease that leads to blindness in the elderly population. In the early 2000s, nAMD resulted in irreversible vision loss and blindness with no available treatment options. However, there have been breakthrough adva...
Autores principales: | Moon, Bo-Hyun, Kim, Younghwa, Kim, Soo-Young |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10454953/ https://www.ncbi.nlm.nih.gov/pubmed/37629185 http://dx.doi.org/10.3390/ijms241613004 |
Ejemplares similares
-
Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor
por: Moon, Da Ru Chi, et al.
Publicado: (2015) -
Ten-year outcome of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration
por: Upasani, Deepa, et al.
Publicado: (2021) -
Effects of delay in anti-vascular endothelial growth factor intravitreal injections for neovascular age-related macular degeneration
por: Hanhart, Joel, et al.
Publicado: (2022) -
Patient Preferences Associated with Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
por: Bhagat, Davis, et al.
Publicado: (2020) -
Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration
por: Cheema, Muhammad Raza, et al.
Publicado: (2021)